Detalles de la búsqueda
1.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 36(1): 85-95, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28726132
2.
Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Chemistry
; 21(18): 6921-9, 2015 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25784522
3.
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.
Nat Chem Biol
; 9(9): 548-56, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23892893
4.
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Invest New Drugs
; 32(6): 1167-80, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25193492
5.
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Mol Cancer Ther
; 22(12): 1465-1478, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37722716
6.
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.
Bioorg Med Chem Lett
; 22(1): 96-101, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22154349
7.
Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.
J Biol Chem
; 285(16): 11775-85, 2010 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-20177074
8.
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Bioorg Med Chem Lett
; 21(10): 2969-74, 2011 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21470862
9.
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors.
Pharmaceutics
; 13(4)2021 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33918158
10.
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Nat Chem Biol
; 4(6): 357-65, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18469809
11.
4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Bioorg Med Chem Lett
; 20(22): 6489-94, 2010 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20932759
12.
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
J Med Chem
; 51(3): 487-501, 2008 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-18201066
13.
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.
Nat Commun
; 8: 15772, 2017 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28598431
14.
Kinase selectivity profiling by inhibitor affinity chromatography.
Expert Rev Proteomics
; 1(3): 303-15, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15966827
15.
Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors.
J Med Chem
; 57(24): 10443-54, 2014 Dec 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25474526
16.
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
PLoS One
; 8(3): e58424, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23520509
17.
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Clin Cancer Res
; 19(13): 3520-32, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23674492
18.
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Mol Cancer Ther
; 11(4): 1006-16, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22319201
19.
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Anticancer Res
; 30(12): 4973-85, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21187478
20.
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
J Med Chem
; 53(9): 3532-51, 2010 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20397705